IL17A and COVID-19: Several case reports have shown that the IL‐17A antagonists, secukinumab and ixekizumab, relieve the symptoms of COVID‐19 in patients with psoriasis, suggesting blocking of IL17A as a potential strategy for treatment of COVID‐19.163, 164